标题:Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis
作者:Lv, Jiahui; Wu, Jingde; He, Feng; Qu, Ying; Zhang, Qiuqiong; Yu, Chenggong
作者机构:[Lv, Jiahui; Wu, Jingde; He, Feng; Qu, Ying; Zhang, Qiuqiong; Yu, Chenggong] Shandong Univ, Sch Pharmaceut Sci, Key Lab Chem Biol, Minist Educ, Jinan 更多
通讯作者:Wu, JD
通讯作者地址:[Wu, JD]Shandong Univ, Jinan 250012, Shandong, Peoples R China.
来源:CURRENT MEDICINAL CHEMISTRY
出版年:2018
卷:25
期:42
页码:5847-5859
DOI:10.2174/0929867325666180316121951
关键词:BTK inhibitor; RA; B cell; activity; anti-inflammatory; structure
摘要:Rheumatoid Arthritis (RA) is a chronic autoimmune disease and becomes one of the major causes of disability and work force loss. The presence of abnormal B cell and autoantibodies produced by most RA patients, primarily ACPA and RF, indicate that the function of B cell was involved in the development of RA disease. Accordingly, the drug targeting B cell has become a hot spot in the treatment of RA. Studies have shown that Bruton's tyrosine kinase (BTK) is involved in the regulation of B cell proliferation and activation process. Some small molecule BTK inhibitors have shown excellent inhibition in biological activity analysis and animal models. Therefore, this review will briefly introduce BTK and its role in cell signaling and overview recent progress of BTK inhibitors for RA treatment.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061868612&doi=10.2174%2f0929867325666180316121951&partnerID=40&md5=311f5c8646641cacfefeb7b360989fe2
TOP